key: cord-0802278-up8hfw0e
authors: Maia, Raquel; Melo, Luis; Mendes, João João; Freitas, Paulo Telles
title: Corticosteroids in COVID-19: a double-edged sword – a retrospective study
date: 2021-02-16
journal: Med Intensiva
DOI: 10.1016/j.medin.2021.02.001
sha: c9a885ddf123513243c9cc9a5a629cfb3529a5c7
doc_id: 802278
cord_uid: up8hfw0e

nan

Author contribution: RM, LM, JJM and PTF were responsible for the study conception and manuscript draft. RM and LM collected data. All authors read and approved the final manuscript.

Ethics approval: Data extraction and analysis was approved by the local IRB. The current research has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Consent to participate: Verbal consent was obtained from patients or closest relative before data extraction Consent for publication: Consent for publication was obtained approved by the local IRB.

Availability of data and material (data transparency): Available on request. We plotted the duration of mechanical ventilation and cumulative corticosteroid dose (expressed as methylprednisolone equivalent dose) and invasive mechanical ventilation duration ( Figure 1A ). We used a cubic spline regression model to plot the relationship between the two variables, using three knots at the 25 th , 50 th and 75 th percentile -namely 160mg, 520mg and 960mg ( Figure 1B ). There was a strong correlation between total corticosteroid dose and ventilation days (p<0.001), following a U-shaped pattern. The shortest ventilation time associated with a cumulative dose of Page 4 of 6 J o u r n a l P r e -p r o o f 4 560mg, while higher doses were associated with longer duration of mechanical ventilation. In order to correct for possible longer duration of treatment with corticosteroids due to inertia we looked at the relation between total duration of mechanical ventilation and methylprednisolone-free ventilation days. After controlling for methylprednisolone-free ventilation days the correlation remained significant (p<0.001). There was no correlation with increased infection rates or mortality, but we found a strong correlation between higher cumulative doses of corticosteroids and ICUacquired myopathy (p=0.03).

This study has some limitations. Given the retrospective nature of the cohort and the change in evidence regarding the efficacy of treatments in COVID-19, treatment was not standardized for all patients. Similarly, the dose and duration of corticosteroid varied among patients and tapering was done based on individual patient condition, as per the CIRCI Guideline. The mean dose of methylprednisolone used in our cohort was 653mg. Despite this heterogeneity, the mortality rate was distributed evenly throughout the 5-month period.

In sum, our analysis suggests that corticosteroid therapy in COVID-19 needs to be carefully titrated and readily tampered when clinical improvement occurs, given the lack of evidence for benefit of higher doses. Considering current evidence, we suggest that prolonged treatment with corticosteroids in COVID-19 should be avoided. 

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial

Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis